Santhera acquires Oy Juvantia Pharma and its dyskinesia candidate
This article was originally published in Scrip
Executive Summary
Santhera Pharmaceuticals has exercised its option to acquire the Finnish company Oy Juvantia Pharma in order to secure all rights to the dyskinesia treatment JP-1730 (fipamezole).